Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Early stage schizophrenia data have seen the group double in value, but there are a couple of sticking points.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
It's official: dramatic share price jumps in response to clinical data have become more common.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.